Human Immunodeficiency Virus-1 Drug Resistance Patterns Among Adult Patients Failing Second-Line Protease Inhibitor-Containing Regimens in Namibia, 2010–2015

Domaine:

healthcare

Type de record:

paper

Créateur:

SouAndClaAnd

Éditeur:

Oxf

Hôte:

Abstract Three hundred sixty-six adult patients in Namibia with second-line virologic failures were evaluated for human immunodeficiency virus drug-resistant (HIVDR) mutations. Less than half (41.5%) harbored ≥1 HIVDR mutations to standardized second-line antiretroviral therapy (ART) regimen. Optimizing adherence, viral load monitoring, and genotyping are critical to prevent emergence of resistance, as well as unnecessary switching to costly third-line ART regimens.

Visit

doi.org

Similaires

HIV drug resistance and third line treatment outcomes in patients failing: Protease Inhibitor based second-line antiretroviral therapy in ZimbabweProtease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South AfricaMajor protease inhibitor drug resistance mutations among patients with virological failure on second-line antiretroviral therapy in Zimbabwe: a retrospective cross-sectional studyHIV-1 Viral Load and Resistance in Genital Secretions in Patients Taking Protease-Inhibitor-Based Second-Line Therapy in AfricaProtease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan AfricaCirculating plasma microRNA expression profiles associated with virological failure and HIV drug resistance among adults receiving second-line protease inhibitor-based antiretroviral therapy in Zimbabwe

HIV drug resistance and third line treatment outcomes in patients failing: Protease Inhibitor based second-line antiretroviral therapy in Zimbabwe

Introduction: We set out to assess the distribution of HIV drug resistance mutations and their risk

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa

Limited data exist on HIV-1 drug resistance patterns in South Africa following second-line protease-

Major protease inhibitor drug resistance mutations among patients with virological failure on second-line antiretroviral therapy in Zimbabwe: a retrospective cross-sectional study

Abstract Background Virological fail

HIV-1 Viral Load and Resistance in Genital Secretions in Patients Taking Protease-Inhibitor-Based Second-Line Therapy in Africa

Background HIV is transmitted primarily through sexual intercourse, and the ob

Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa

Background.
As antiretroviral therapy (ART) programs in sub-Saharan Africa mature, increasing n

Circulating plasma microRNA expression profiles associated with virological failure and HIV drug resistance among adults receiving second-line protease inhibitor-based antiretroviral therapy in Zimbabwe

Abstract Background Virological failure (VF) and HIV drug resistance (HIVDR) rema